The Enterobacter cloacae complex comprises a group of closely related Gram-negative bacteria that have emerged as significant opportunistic pathogens within healthcare settings worldwide. These ...

We are providing an unedited version of this manuscript to give early access to its findings. Before final publication, the manuscript will undergo further editing. Please note there may be errors ...

In a major advance for infectious disease treatment, researchers from Monash University and The Alfred have developed a bespoke phage therapy product that uses bacterial viruses, known as ...

FDA approved Utebzi, an oral carbapenem antibiotic developed by GSK in partnership with Spero Therapeutics, for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in ...

The treatment, named Entelli-02, is a five-phage cocktail designed specifically to target Enterobacter cloacae complex (ECC), a group of bacteria responsible for severe, often difficult-to-treat ...